Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial

BACKGROUND: Antibody-mediated rejection (ABMR) is a cardinal cause of renal allograft loss. This rejection type, which may occur at any time after transplantation, commonly presents as a continuum of microvascular inflammation (MVI) culminating in chronic tissue injury. While the clinical relevance...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayer, Katharina A., Budde, Klemens, Halloran, Philip F., Doberer, Konstantin, Rostaing, Lionel, Eskandary, Farsad, Christamentl, Anna, Wahrmann, Markus, Regele, Heinz, Schranz, Sabine, Ely, Sarah, Firbas, Christa, Schörgenhofer, Christian, Kainz, Alexander, Loupy, Alexandre, Härtle, Stefan, Boxhammer, Rainer, Jilma, Bernd, Böhmig, Georg A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990453/
https://www.ncbi.nlm.nih.gov/pubmed/35395951
http://dx.doi.org/10.1186/s13063-022-06198-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990453/
https://www.ncbi.nlm.nih.gov/pubmed/35395951
http://dx.doi.org/10.1186/s13063-022-06198-9

Ejemplares similares